1. Introduction and Meaning

The Corporate Genome Accountability Doctrine Governance is a proposed interdisciplinary legal and corporate-governance framework that examines the legal responsibility of corporations involved in genetic research, genomic data processing, genetic engineering, biotechnology, gene editing, genetic testing, and commercial exploitation of genetic information.

The doctrine seeks to establish that corporations must remain legally accountable for the consequences of their activities involving human genetic material, genomic information, inherited biological characteristics, and genetic technologies.

It combines principles of:

Corporate legal accountability.

Genetic privacy and data protection.

Bioethics and human dignity.

Corporate directors' duties and fiduciary responsibility.

Scientific transparency and informed consent.

Biotechnology safety and risk management.

Consumer protection and non-discrimination.

Environmental and intergenerational justice.

Central proposition: A corporation must not treat the human genome merely as a commercial asset. Its collection, analysis, modification, storage, transfer, and commercial use must comply with human-rights protections, scientific safeguards, and enforceable accountability obligations.

The doctrine is not currently a separately codified or universally recognised legal doctrine. It is a proposed governance framework constructed from existing corporate, constitutional, privacy, biotechnology, and human-rights principles.

2. Objectives of the Doctrine

The doctrine has the following principal objectives:

Prevent unauthorised collection and exploitation of human genetic information.

Establish corporate liability for negligent genomic research and biotechnology operations.

Protect individuals against genetic discrimination in employment, insurance, healthcare, and commercial transactions.

Ensure genuine informed consent before genetic testing and research.

Establish accountability for genetic-data breaches.

Prevent misleading commercial claims concerning genetic treatments and enhancement technologies.

Protect vulnerable populations participating in genomic research.

Ensure that corporate profits do not override human dignity and biological autonomy.

3. Core Legal Principles

A. Principle of Genetic Dignity

Genetic information is closely connected with personal identity, bodily autonomy, family relationships, and future health possibilities.

Corporations should therefore not use genetic characteristics to determine an individual's social worth, employability, insurability, or commercial value.

The principle draws support from Articles 1, 2, 4, 5 and 6 of UNESCO's Universal Declaration on the Human Genome and Human Rights.

Article 4 is particularly important because it distinguishes the human genome in its natural state from commercial exploitation.

Legal Affairs+1

B. Principle of Informed Genetic Consent

A corporation collecting genetic material must ensure that consent is:

Voluntary and free from coercion.

Informed about the research objectives.

Specific about the proposed use of genetic samples.

Transparent about commercial exploitation.

Clear about storage and sharing arrangements.

Accompanied by information about withdrawal rights, where applicable.

A person agreeing to a medical genetic test does not automatically consent to unlimited commercial research, pharmaceutical development, or third-party data transfers.

C. Principle of Genetic Data Confidentiality

Corporate entities must establish safeguards against:

Unauthorised access to genomic databases.

Disclosure of genetic information to employers.

Commercial transfer without an appropriate legal basis.

Re-identification of supposedly anonymised genetic records.

Unauthorised cross-border transfers.

Use of genetic information for discriminatory profiling.

Genetic information can also reveal information about biological relatives who never directly participated in the research. This creates a distinctive privacy challenge.

D. Principle of Corporate Scientific Responsibility

A biotechnology corporation must assess foreseeable scientific risks before introducing genetic technologies into clinical or commercial markets.

Its responsibilities may include:

Scientific validation.

Independent ethics review.

Laboratory quality control.

Adverse-event reporting.

Accurate public disclosure.

Long-term monitoring where scientifically and legally required.

Correction of misleading genetic-test interpretations.

E. Principle of Intergenerational Accountability

Genetic interventions can potentially have consequences extending beyond the individual receiving treatment.

Therefore, corporate governance must distinguish between:

Somatic gene editing, which affects the treated individual.

Germline gene editing, which may affect descendants.

Heritable genetic modification, which raises broader ethical and regulatory concerns.

Corporate commercial interests cannot independently justify interventions carrying inadequately assessed intergenerational risks.

4. Indian Legal Framework

The doctrine can be developed using the following Indian constitutional and statutory provisions.

Important current-law qualification: The Digital Personal Data Protection Act, 2023 has a phased commencement. The notification dated 13 November 2025 brought specified provisions into force immediately, while the principal processing obligations in Sections 3–17 are scheduled to commence 18 months after publication. Accordingly, as of 4 November 2026, those principal obligations have not yet commenced.

IndiaCode+1

Constitutional significance

The Supreme Court's recognition of privacy as a fundamental right provides an important foundation for protecting genetic information.

Genetic privacy can be understood as an extension of informational privacy because genomic records may reveal intimate information about an individual's biological characteristics, predispositions, and family relationships.

5. Landmark Case Laws and Their Relevance

The following decisions provide judicial foundations for developing the proposed doctrine. Some concern genetic information directly, while others establish broader principles of privacy, consent, biotechnology ownership, and corporate responsibility.

1. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Indian Supreme Court

Citation: (2017) 10 SCC 1.

Legal issue: Whether privacy is a constitutionally protected fundamental right.

Judgment: The Supreme Court unanimously recognised privacy as a fundamental right protected under Article 21 and other freedoms in Part III of the Constitution.

Relevance to corporate genome accountability:

Genetic information falls within the broader concept of informational privacy.

Individuals should retain meaningful control over sensitive personal information.

Collection and processing of intimate information require a constitutionally legitimate basis.

Commercial interests do not automatically override individual privacy.

Doctrinal application: A corporation collecting genetic data without adequate consent or safeguards may face legal challenges under applicable privacy and data-protection law.

2. Samira Kohli v. Dr. Prabha Manchanda (2008)

Indian Supreme Court

Citation: (2008) 2 SCC 1.

Legal issue: Validity and scope of informed consent in medical treatment.

Judgment: The Supreme Court explained that consent must be real and informed, and that consent for one medical procedure cannot ordinarily be treated as consent for a materially different procedure.

Relevance:

A genetic-testing company cannot automatically extend consent for diagnostic testing to unrelated commercial research, genetic experimentation, or other uses.

Doctrinal application: Corporate genetic research programmes must distinguish between consent for diagnosis, treatment, research, storage, and commercial utilisation.

3. Sharda v. Dharmpal (2003)

Citation: (2003) 4 SCC 493.

Legal issue: Medical examination and bodily autonomy in judicial proceedings.

Judgment: The Supreme Court considered the circumstances in which a court may direct medical examination in matrimonial proceedings.

Relevance:

The judgment illustrates the tension between personal autonomy and legitimate legal interests in obtaining biological or medical evidence.

Its application to compulsory corporate genetic testing is limited; it does not establish a general corporate power to collect genetic samples.

4. Moore v. Regents of the University of California (1990)

United States Supreme Court of California

Citation: 51 Cal. 3d 120 (1990).

Legal issue: Whether a patient retains property rights in removed biological cells subsequently used for commercial research.

Judgment: The court rejected Moore's conversion claim concerning the patented cell line but allowed claims relating to the physician's failure to disclose relevant research and economic interests.

Relevance:

This decision raises important questions about:

Commercialisation of human biological materials.

Disclosure of financial interests.

Patient consent.

Conflicts of interest in biomedical research.

Corporate and institutional accountability.

Doctrinal application: A corporation should disclose material commercial interests and research purposes when obtaining biological samples under an informed-consent framework.

5. Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

United States Supreme Court

Citation: 569 U.S. 576 (2013).

Legal issue: Whether naturally occurring human genes can be patented merely because they have been isolated.

Judgment: The Supreme Court held that naturally occurring DNA is not patent-eligible merely because it has been isolated. It distinguished synthetically created complementary DNA (cDNA), subject to the limitations discussed in the judgment.

Relevance:

This decision is significant for corporate genomic governance because it limits attempts to claim exclusive patent rights over naturally occurring genetic material.

Doctrinal application: Corporate biotechnology innovation must respect the distinction between discoveries of naturally occurring biological material and patentable human inventions.

6. Greenberg v. Miami Children's Hospital Research Institute, Inc. (2003)

Citation: 264 F. Supp. 2d 1064 (S.D. Fla. 2003).

Legal issue: Donor expectations, research consent, and commercial patenting of genetic discoveries.

Judgment: The US District Court addressed claims brought by individuals and organisations that had contributed genetic material and research assistance to the Canavan disease research project.

Relevance:

The case raises questions about the relationship between research participation, commercial exploitation, donor expectations, and disclosure.

Doctrinal application: Genetic research organisations should clearly communicate potential commercial uses, intellectual-property arrangements, and benefit-sharing policies.

7. National Federation of the Blind v. United States Department of Transportation (2001)

This is not a genomic-data decision and is not a direct precedent for the doctrine. It is not necessary to rely on it as a foundational genetic accountability authority.

The stronger authorities are the privacy, informed-consent, and biotechnology decisions discussed above.

6. S. and Marper v. United Kingdom (2008)

European Court of Human Rights

Citation: Applications Nos. 30562/04 and 30566/04, Grand Chamber, 4 December 2008.

Legal issue: Retention of fingerprints, cellular samples, and DNA profiles of individuals who had not been convicted of offences.

Judgment: The Court found that the blanket and indiscriminate retention of such material violated Article 8 of the European Convention on Human Rights.

Relevance:

DNA information deserves heightened privacy protection.

Indefinite retention can interfere with personal privacy.

Data collection and retention must be proportionate.

The sensitivity of genetic information requires appropriate safeguards.

Doctrinal application: Corporations operating genomic databases should adopt purpose-specific retention periods and appropriate deletion procedures.

7. Gaughran v. United Kingdom (2020)

Citation: Application No. 45245/15, European Court of Human Rights.

Legal issue: Indefinite retention of biometric information, including DNA profiles and fingerprints.

Judgment: The Court found a violation of Article 8 because the retention regime lacked sufficient safeguards and proportionality.

Relevance: This judgment supports the principle that possession of genetic information does not create an unlimited right to retain or exploit it.

Doctrinal application: Corporate genomic repositories should periodically review whether continued storage is necessary and legally justified.

8. Association for Molecular Pathology v. Myriad Genetics (2013): Corporate Patent Accountability

This case deserves particular attention because it addresses the boundary between scientific discovery and corporate ownership.

The judgment establishes that naturally occurring DNA sequences cannot become patentable inventions merely through isolation.

Its significance for corporate genome governance is that biotechnology companies must distinguish between:

Naturally occurring genetic information.

Human-created genetic technologies.

Laboratory-developed diagnostic methods.

Patentable synthetic biological inventions.

The decision does not prohibit all commercial activity involving genetic research. It establishes limits on patent eligibility under US law.

6. Corporate Liability Under the Doctrine

The proposed doctrine recognises several categories of corporate responsibility.

An important distinction must be maintained: corporate responsibility does not automatically mean that every corporate officer is personally liable. Personal criminal responsibility requires the relevant statutory basis and proof of the individual's legally required involvement, knowledge, consent, neglect, or other elements.

7. Corporate Directors' Fiduciary and Governance Duties

The Companies Act, 2013 provides a significant foundation for corporate accountability.

Section 166 – Duties of Directors

Directors must act in accordance with the company's articles, promote the company's objectives for the benefit of members as a whole, and act in good faith in the interests of the company, employees, shareholders, the community, and environmental protection.

They must also exercise due and reasonable care, skill and diligence.

Application: Directors of biotechnology and genomic-data companies should oversee material risks involving genetic privacy, research ethics, patient consent, product safety, and commercial conflicts of interest.

Section 134 – Board Responsibility

Board reporting and internal financial and governance controls can provide mechanisms for disclosing material corporate risks.

A proposed genome-accountability governance system should require the board to review:

Genomic-data protection policies.

Research ethics compliance.

Biological sample management.

Genetic-testing accuracy.

Third-party data-sharing arrangements.

Biotechnology safety incidents.

Regulatory investigations.

Independent oversight

A corporation should establish a multidisciplinary genomic ethics and accountability committee comprising:

Legal and compliance specialists.

Genetic researchers.

Bioethicists.

Data-protection professionals.

Medical experts.

Independent public-interest representatives.

The committee should review sensitive research, investigate complaints, monitor consent procedures, and report serious compliance failures to the board.

8. Corporate Genome Accountability Governance Model

The proposed doctrine can be operationalised through seven governance pillars.

Seven-pillar governance architecture

Pillar 1

Genetic consent governance

Documented consent, purpose limitation, withdrawal procedures, and disclosure of commercial interests.

Pillar 2

Genomic privacy governance

Encryption, access controls, data minimisation, confidentiality, and re-identification risk assessment.

Pillar 3

Scientific integrity governance

Independent peer review, validated research methods, reproducibility, and accurate reporting.

Pillar 4

Corporate liability governance

Internal investigations, responsibility allocation, compliance monitoring, and remediation.

Pillar 5

Genetic equality governance

Prevention of discriminatory genetic profiling in employment, insurance, healthcare, and other commercial decisions.

Pillar 6

Biotechnology risk governance

Pre-market risk assessment, laboratory quality assurance, adverse-event monitoring, and safety reporting.

Pillar 7

Intergenerational accountability

Special scrutiny of potentially heritable interventions, long-term consequences, and public-interest safeguards.

9. Corporate Genome Accountability and Genetic Discrimination

One of the most significant applications of the doctrine concerns genetic discrimination.

Imagine a company obtaining an employee's genetic information and discovering a predisposition to a hereditary disease.

The company subsequently uses this information to:

Deny employment.

Reduce promotion opportunities.

Increase insurance-related costs.

Exclude individuals from certain corporate benefits.

Create discriminatory employee categories.

Such conduct raises serious legal and ethical concerns.

In India, constitutional equality and privacy principles, applicable employment law, and relevant data-protection provisions may provide legal grounds for challenging particular conduct.

Internationally, the United States Genetic Information Nondiscrimination Act (GINA), 2008 provides specific protections against genetic discrimination in health insurance and employment, subject to statutory exceptions and limitations.

The doctrine proposes that genetic information should not become an independent instrument for corporate exclusion or economic exploitation.

10. Commercial Exploitation and Ownership of Genomic Information

Corporate biotechnology businesses may generate commercial value through:

Genetic diagnostic products.

Pharmaceutical research.

Gene-editing technologies.

Genomic databases.

Personalised medicine.

Genetic screening platforms.

Artificial intelligence-based genomic analysis.

However, commercial value does not automatically establish unrestricted ownership over human biological materials or personal genetic information.

The legal framework must distinguish between:

UNESCO's International Declaration on Human Genetic Data, 2003, is particularly important because it addresses consent, privacy, confidentiality, discrimination, accuracy, security, and the sharing of research benefits.

Legal Affairs+1

11. International Legal and Regulatory Framework

The doctrine can draw upon several international instruments.

A. UNESCO Universal Declaration on the Human Genome and Human Rights, 1997

Important principles include:

Human dignity irrespective of genetic characteristics.

Protection against genetic discrimination.

Informed consent.

Confidentiality of genetic information.

Scientific responsibility.

B. UNESCO International Declaration on Human Genetic Data, 2003

It provides principles concerning:

Genetic-data collection and storage.

Consent and withdrawal.

Privacy and confidentiality.

Protection against discrimination.

Accuracy and security.

Research benefit-sharing.

C. Genetic Information Nondiscrimination Act, 2008 (United States)

Provides specific employment and health-insurance protections against certain forms of genetic discrimination.

D. European Union General Data Protection Regulation (GDPR)

Article 9 treats genetic data as a special category of personal data, subject to restrictions and specified exceptions.

Together, these instruments provide an important comparative foundation for corporate genomic accountability.

12. Major Legal Challenges

The implementation of the doctrine presents several challenges.

1. Scientific uncertainty: Genetic research may produce uncertain or incomplete conclusions, making it difficult to determine corporate negligence.

2. Cross-border jurisdiction: Genetic databases may be operated in one country, processed in another, and commercially exploited elsewhere.

3. Anonymisation difficulties: Genetic information may remain identifiable through comparison with other datasets.

4. Intellectual-property conflicts: Commercial research interests may conflict with individual consent, access, and benefit-sharing expectations.

5. Intergenerational consequences: Heritable genetic modifications raise questions about the rights and interests of future generations.

6. Corporate group responsibility: Parent companies, subsidiaries, laboratories, research contractors, and technology providers may share responsibility for different parts of a genomic-data operation.

7. Regulatory fragmentation: Privacy, biotechnology, medical research, consumer protection, and corporate law may apply simultaneously without a single comprehensive genomic accountability statute.

13. Proposed Corporate Genome Accountability Compliance Test

A useful academic contribution would be to formulate a seven-stage test for assessing corporate conduct.

A failure at any stage should trigger appropriate investigation, although the legal consequences must depend on the applicable statute, contractual obligations, and established elements of liability.

14. Emerging Issues: AI, Corporate Genomics and Future Governance

The doctrine becomes particularly important when genetic information is processed using artificial intelligence.

Consider a corporation operating an AI-powered genomic prediction platform.

The platform may:

Predict disease susceptibility.

Classify individuals according to genetic risk.

Recommend personalised medical interventions.

Identify potential pharmaceutical targets.

Combine genomic information with behavioural and lifestyle data.

Generate commercial risk scores.

This creates a new category of corporate accountability: algorithmic genomic governance.

Corporate responsibility should extend to the accuracy, explainability, security, fairness, and lawful use of genomic prediction systems.

A company should not escape accountability merely because a discriminatory decision or harmful recommendation was generated by an automated algorithm rather than directly by a human employee.

The appropriate liability will nevertheless depend on the applicable law, the corporation's role, foreseeability, causation, and other legal requirements.

15. Critical Judicial Principles: Comparative Summary

16. Critical Analysis: Is Corporate Genome Accountability a New Branch of Corporate Law?

The proposed doctrine represents a possible development of corporate governance beyond traditional financial and operational accountability.

Traditional corporate governance primarily addresses:

Shareholder interests.

Directors' duties.

Financial transparency.

Corporate fraud.

Regulatory compliance.

Stakeholder protection.

Corporate genome accountability introduces additional dimensions:

Biological autonomy.

Genetic-data sovereignty.

Scientific responsibility.

Intergenerational protection.

Genomic equality.

Biotechnology risk allocation.

Its central innovation is to recognise that corporate decisions involving human genetic information can affect not only individuals but also families, communities, and potentially future generations.

However, the doctrine should not be interpreted as creating automatic corporate ownership of genetic information, absolute property rights in every biological sample, or strict liability for every adverse scientific outcome. These matters must be determined under applicable law.

17. Conclusion

The Corporate Genome Accountability Doctrine Governance proposes a human-centred approach to corporate responsibility in the genomic and biotechnology industries.

Its fundamental purpose is to ensure that commercial innovation remains consistent with privacy, informed consent, human dignity, scientific integrity, equality, and public welfare.

The judgments in Puttaswamy, Samira Kohli, Moore, Myriad Genetics, Greenberg, and S. and Marper provide important judicial foundations for constructing this framework.

For India, the doctrine could contribute to the development of a more comprehensive legal architecture connecting constitutional privacy, corporate directors' duties, biotechnology regulation, research ethics, consumer protection, and digital-data governance.

The ultimate proposition is that corporate control over genomic technology must be accompanied by corresponding legal responsibility for the protection of human dignity, genetic autonomy, and biological privacy.

18. Suggested Academic Research Proposition

For advanced legal research, the doctrine can be formulated as follows:

Corporate Genome Accountability Doctrine is a proposed normative framework under which corporations engaged in the collection, processing, modification, storage, commercialisation, or algorithmic interpretation of human genetic material must discharge enforceable duties of consent, confidentiality, scientific integrity, non-discrimination, risk prevention, transparency, and remedial accountability.

Suggested research title:

Corporate Genome Accountability: Developing a Constitutional, Fiduciary and Bioethical Framework for Corporate Responsibility in the Age of Genomic Capitalism.

Research questions:

Can human genetic information be treated as a distinct category of legally protected corporate-governance risk?

What fiduciary duties should directors of genomic biotechnology corporations discharge?

Can corporations be held responsible for algorithmic genetic discrimination?

How should genetic-data commercialisation be reconciled with informed consent?

Should India develop a dedicated statutory framework for corporate genomic accountability?

Academic assessment: This is a promising interdisciplinary research concept, particularly for doctoral research combining Corporate Law, Constitutional Law, Biotechnology Law, Bioethics, and Data Protection Law. It should be presented as a proposed doctrine rather than an already established rule of Indian law.